News Details

PALM SPRINGS, Calif. – PerkinElmer Life and Analytical Sciences, a global leader in life science research, drug discovery and cellular science, today announced several high-throughput product technologies and a new consultative approach to optimizing laboratory automation, that focus on improving labs' application flexibility, efficiency, and robustness at LabAutomation 2008, Jan. 27-30, Palm Springs, Calif., booth #427.

“Clinical and drug discovery research is moving at such an accelerated pace that our new technologies and services have been developed to optimize lab performance through high-throughput screening (HTS), and greater instrument flexibility and automation,” said Dr. Richard Eglen, President, Molecular Medicine, PerkinElmer Life and Analytical Sciences. Providing Greater Application Flexibility with EnVision^® Microplate Reader with Monochromator Option PerkinElmer has introduced technology advancements that optimize instrument performance by integrating filter-based and monochromator-based platforms in its established EnVision^® microplate reader product line. The dual-system platform lets researchers choose their high-throughput detection method, and provides faster assay turnaround. The new monochromator option is available in two formats: the Absorbance Monochromator measures absorbance assays with a single monochromator, while the Fluorescence Intensity Monochromator measures absorbance and fluorescence intensity with a high performance quad monochromator package. The monochromator option is part of a highly flexible instrument system. It can be combined with other EnVision^® options, including the TRF (time-resolved fluorescence) LASER; can easily be integrated into robotic systems; and can accept microplates up to 3456 wells.

Powerful Functionality in a Smaller Footprint with LumiLux^® CS Cellular Luminescence Platform

As a complement to the current LumiLux Cellular Screening Platform, PerkinElmer has announced the new LumiLux^® CS Cellular Luminescence platform, a compact design that preserves the exceptional performance and sensitivity of the current LumiLux^® platform. The much smaller footprint saves valuable space in crowded labs, and meets the increased demand of HTS labs switching from kinetic fluorescence to flash luminescence technologies. The compact design allows for standalone operation for lower throughput applications or integration into new or existing robotic platforms for HTS screening. The LumiLux^® platforms are the only dedicated flash luminescence instruments that enable simultaneous 1536 “inject and read” flash luminescence assays, allowing laboratories to produce over 200,000 data points per day.

Rapid Automation Platform Development with Integration Solutions Services

PerkinElmer has introduced an enhanced consultative business approach to address the customers need for a unique and customized automated solution. The Integration Solutions service deploys PerkinElmer's extensive expertise in liquid handling, robotics, detection, software and reagent chemistries to partner with our customers for development of application solutions, assay validation, systems integration, engineering services and new product development.

“PerkinElmer has the reagent, detection and automation experience and the resources to be a critical partner for customers looking for an automation solution that meets their specific application requirements,” said Nance Hall, Vice President of Automation and Detection Solutions at PerkinElmer. “The Integration Solutions approach addresses applications in life science, clinical research, and analytical sciences, utilizing core technologies and flexible platforms such as the JANUS^® Automated Workstation and the EnVision and Victor^™ microplate readers.”

Greater Efficiency and Error Reduction with New High-Throughput Microplates

PerkinElmer introduced 20 new high-throughput microplates. The OptiPlate^™, CulturPlate^™, SpectraPlate^™ 1536 well models have an exclusive, innovative plate height of 14.35 mm and the same overall dimensions as 94-and 384-well plates. The new microplates provide for a single automation protocol, which can result in reduced error since no adjustment is required when 96-and 384-well plates are changed to 1536-well plates. The new plates also have a wider gripping area for smoother robotic operations.

Another new microplate design, a light-gray AlphaPlate^™, was developed for the AlphaScreen^® and AlphaLISA^™ biomarker detection assays. Preliminary tests have shown that the AlphaPlate can significantly reduce crosstalk when compared to standard white microplates, and provides for enhanced precision in chemiluminescence, with greater sensitivity.

For more information about all the new product technologies and services, visit www.perkinelmer.com.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer Inc.'s Life and Analytical Sciences business unit provides fully integrated, innovative solutions, leveraging deep scientific expertise and dedication to fulfilling customer needs to help scientists advance the pace and precision of their research and testing. It is a leading provider of diagnostic and detection instruments, reagents, software and services for advanced cellular science research and drug discovery, genetic screening, medical imaging, environmental, quality assurance and the health sciences industries.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

For further information regarding PerkinElmer, please contact:

Media Contact:

Dara Cothran
Euro RSCG Worldwide PR
(212) 367-6814
dara.cothran@eurorscg.com